We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Thermo Fisher Scientific Announces Launch of Immune Cell Types Family of Assays

Thermo Fisher Scientific Announces Launch of Immune Cell Types Family of Assays content piece image
Applied Biosystems PureQuant Assays
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
Applied Biosystems PureQuant Assays are a family of assays that accurately identify and quantify specific immune cell types in a mixed population of cells. Designed for in-process and release testing of cell-based therapeutics, these assays measure genomic DNA methylation at sites that are unique to a specific immune cell type. With standards and controls built into each assay, they are ready to be seamlessly integrated into cell therapy workflows.

With the launch of the Applied Biosystems PureQuant Assays, Thermo Fisher Scientific has enhanced its industry-leading cell and gene therapy portfolio by providing an innovative method for identity and purity testing of cell-based therapeutics.

• Proven performance: The core technology has been used for identification and quantification of immune cell types for more than a decade.
• Easily standardized: The qPCR method enables consistent results across multiple users, instruments and sites.
• Facilitates regulatory filings: Regulatory support file provided upon request; established performance specifications following ICHQ2(R1) guidelines.
• Scheduling flexibility: The assay can be performed using fresh or frozen cells/gDNA.